Hostname: page-component-848d4c4894-8kt4b Total loading time: 0 Render date: 2024-06-24T20:31:32.653Z Has data issue: false hasContentIssue false

Development of a National Public Pharmaceutical Research and Development Institute

Published online by Cambridge University Press:  01 January 2021

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Columns: Health Policy Portal
Copyright
Copyright © American Society of Law, Medicine and Ethics 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Level, N.M., “High Drug Costs Outweigh ‘Medicare for All’ as Top Health-care Issue for Voters,” LA Times, available at <https://www.latimes.com/politics/story/2020-01-21/high-cost-prescription-drugs-campaign-issue> (last visited February 27, 2020).+(last+visited+February+27,+2020).>Google Scholar
Kesselheim, A.S., Avorn, J., and Sarpatwari, A., “The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform,” JAMA 316, no. 8 (2016): 858871.CrossRefGoogle Scholar
Wineinger, N.E., Zhang, Y., and Topol, E.J., “Trends in Prices of Popular Brand-Name Prescription Drugs in the United States,” JAMA Network Open 2, no. 5 (2019): e194791.CrossRefGoogle Scholar
Global oncology trends 2019, IQVIA Institute for Human Data Science, available at <https://www.iqvia.com/insights/the-iqvia-institute/reports/global-oncology-trends-2019> (last visited February 27, 2020).+(last+visited+February+27,+2020).>Google Scholar
Pharmaceutical company drug sales as compared to R&D outlays, Knowledge Ecology International, available at <http://drugdatabase.info/pharmaceutical-company-drug-sales-as-compared-to-rd-outlays/> (last visited February 27, 2020).+(last+visited+February+27,+2020).>Google Scholar
Galkina, C.E., Beierlein, J.M., Khanuja, N.S., McNamee, L.M., and Ledley, F.D., “Contribution of NIH Funding to New Drug Approvals 2010-2016,” Proceedings of the National Academy of Sciences of the USA 115, no. 10 (2018): 23292334.Google Scholar
Larsen, J.C. and Disbrow, G.L., “Project BioShield and the Biomedical Advanced Research Development Authority: A Ten Year Progress Report on Meeting U.S. Preparedness Objectives for Threat Agents,” Clinical Infectious Diseases 64, no. 10 (2017):14301434; Kaiser, J., “Texas Voters Approve Second Life for State Cancer Funding Agency,” Science, available at <https://www.sciencemag.org/news/2019/11/texas-voters-approve-second-life-state-cancer-funding-agency> (last visited February 27, 2020).Google Scholar
Nayak, R., Avorn, J., and Kesselheim, A.S., “Public Sector Financial Support for Late Stage Discovery of New Drugs in the United States: Cohort Study,” BMJ 367 (2019): l5766.Google Scholar
Sarpatwari, A., LaPidus, A.K., and Kesselheim, A.S., “Revisiting the National Institutes of Health Fair Pricing Condition: Promoting Drugs Developed with Government Support,” Annals of Internal Medicine (2020)(E-pub ahead of print).CrossRefGoogle Scholar
Kesselheim, A.S., Avorn, J., and Sarpatwari, A., “The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform,” JAMA 316, no. 8 (2016): 858871.Google Scholar
Swanson, A., “Big Pharmaceutical Companies are Spending Far More on Marketing than Research,” Washington Post, available at <https://www.washingtonpost.com/news/wonk/wp/2015/02/11/big-pharmaceutical-companies-are-spending-far-more-on-marketing-than-research> (last visited February 27, 2020).+(last+visited+February+27,+2020).>Google Scholar
Kaltenboeck, A., Calsyn, M., Frederix, G.W.J., et al., “Grounding Value-Based Drug Pricing in Population Health,” Clinical Pharmacology & Therapeutics (2020) (E-pub ahead of print).Google Scholar
Dunn, A., “Amgen Exists Neuroscience R&D as Pharma Pulls Back from Field,” BioPharma Dive, available at <https://www.biopharmadive.com/news/amgen-exits-neuroscience-rd-as-pharma-pulls-back-from-field/566157/> (last visited March 13, 2020).+(last+visited+March+13,+2020).>Google Scholar
World Health Organization, “Lack of New Antibiotics Threatens Global Efforts to Contain Drug-Resistant Infections,” available at <https://www.who.int/news-room/detail/17-01-2020-17-01-2020-lack-of-new-antibiotics-threatens-global-efforts-to-contain-drug-resistant-infections> (last visited February 27, 2020).+(last+visited+February+27,+2020).>Google Scholar
World Health Organization, 2019 Antibacterial Agents in Clinical Development: An Analysis of the Antibacterial Clinical Development Pipeline, available at <https://apps.who.int/iris/bitstream/handle/10665/330420/9789240000193-eng.pdf> (last visited February 27, 2020).+(last+visited+February+27,+2020).>Google Scholar
Baker, D., “The Future of the Pharmaceutical Industry: Beyond Government-Granted Monopolies,” CEPR, available at <http://cepr.net/images//stories/reports/pharma-industry-2019-03.pdf> (last visited February 27, 2020).+(last+visited+February+27,+2020).>Google Scholar
“Savings Available under Full Generic Substitution of Multiple Source Brand Drugs in Medicare Part D,” U.S. Department of Health and Human Services, available at <https://aspe.hhs.gov/system/files/pdf/259326/DP-Multisource-Brands-in-Part-D.pdf?utm_source=newsletter&utm_medium=email&utmcampaign=newsletter_axiosvitals&stream=top> (last visited February 27, 2020).+(last+visited+February+27,+2020).>Google Scholar
Mazzucato, M., The Entrepreneurial State: Debunking Public vs. Private Sector Myths (New York, NY: Public Affairs; 2015).Google Scholar